The numerous clinical trials in various cancer types, including melanoma, testing AXLi as mono-treatment or in combination with chemo- (in pancreas cancer, NCT03649321), immuno- (in lung cancer, NCT03184571 and melanoma, NCT02872259) or targeted (in melanoma, NCT02872259) therapies reflects a promise in AXL as a therapeutic target. Here, AXL is linked to pancreatic neoplasm.